Weight loss drug’s heart benefits extend to people with heart failure
1 min read
Estimated reading time: 1 minutes
The researchers looked at data from 4,286 people — out of a total of 17,605 from the landmark Semaglutide and Cardiovascular Outcomes (SELECT) trial who were randomly assigned either semaglutide or a placebo — who were followed up over an average of more than three years.
About The Author
Discover more from Life is Pro-Mazing!
Subscribe to get the latest posts sent to your email.
